

Johnson & Johnson Innovative Medicine Pipeline

Key Events in 2026*

POTENTIAL APPROVALS US/EU

✓	US	TREMFYA (guselkumab) Psoriatic Arthritis Structural Damage (APEX)
✓	US	ICOTYDE (icotrokinra)
✓	EU	Psoriasis (ICONIC)
✓	US	IMAAVY (nipocalimab) Warm Autoimmune Hemolytic Anemia (ENERGY)
	EU	AKEEGA (niraparib/abiraterone) M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE)
✓	US	DARZALEX (daratumumab) Frontline multiple myeloma transplant ineligible (CEPHEUS)
✓	US	TECVAYLI (teclistamab)
✓	EU	Multiple Myeloma 1-3PLs (MajesTEC-3)
	EU	TECVAYLI (teclistamab) Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9)
	US	RYBREVANT (amivantamab) Head and Neck Cancer (ORIGAMI-4)

PLANNED SUBMISSIONS US/EU

✓	US	IMAAVY (nipocalimab) Warm Autoimmune Hemolytic Anemia (ENERGY)
	US	CAPLYTA (lumateperone) Bipolar Mania
	US	ERLEADA (apalutamide) Localized Prostate Cancer (ATLAS)
	US	ERLEADA (apalutamide) High Risk Prostate Cancer (PROTEUS)
	US	bleximenib Relapsed Refractory Acute Myeloid Leukemia (cAMeLot-1)
✓	US	TALVEY (talquetamab)
✓	EU	Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumenTAL-3)
✓	US	TALVEY (talquetamab)
✓	EU	Relapsed Refractory Multiple Myeloma CD38 exposed (MonumenTAL-6)
✓	US	TECVAYLI (teclistamab)
✓	EU	Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9)
	EU	TECVAYLI (teclistamab) Multiple Myeloma 1-3PLs (MajesTEC-3)
✓	US	RYBREVANT (amivantamab) Head and Neck Cancer (ORIGAMI-4)
	US	INLEXZO (gemcitabine intravesical delivery system)
	EU	High Risk Non Muscle Invasive Bladder Cancer BCG Experienced (SunRISe-5)

POTENTIAL CLINICAL DATA PRESENTATIONS¹

Phase III

	ICOTYDE (icotrokinra) Psoriasis (ICONIC-ASCEND)	ERLEADA (apalutamide) Localized Prostate Cancer (ATLAS)	✓	JNJ-4804 Co-antibody Therapy Ulcerative Colitis (DUET-UC)
✓	ICOTYDE (icotrokinra) Psoriasis (ICONIC-ADVANCE 1&2 Update)	✓ ERLEADA (apalutamide) High Risk Prostate Cancer (PROTEUS)	✓	JNJ-4804 Co-antibody Therapy Crohn's Disease (DUET-CD)
	icotrokinra Psoriatic Arthritis (ICONIC-PsA)	✓ TALVEY (talquetamab) Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumenTAL-3)	✓	JNJ-4804 Co-antibody Therapy Psoriatic Arthritis (AFFINITY)
✓	ICOTYDE (icotrokinra) Psoriasis (ICONIC-TOTAL Update)	TALVEY (talquetamab) Relapsed Refractory Multiple Myeloma CD38 exposed (MonumenTAL-6)	✓	nipocalimab Systemic Lupus Erythematosus (JASMINE)
✓	CAPLYTA (lumateperone) Bipolar Mania (ITI-007-451)	✓ TECVAYLI (teclistamab) Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9)		bleximenib Relapsed Refractory Acute Myeloid Leukemia (cAMeLot-1)
	CAPLYTA (lumateperone) Bipolar Mania (ITI-007-452)	INLEXZO (gemcitabine intravesical delivery system) High Risk Non Muscle Invasive Bladder Cancer BCG Experienced (SunRISe-5)		pasritamig + JNJ-9401 Prostate Cancer (PCR1001)
✓	IMAAVY (nipocalimab) Warm Autoimmune Hemolytic Anemia (ENERGY)			JNJ-6143 (HLD-0915) Prostate Cancer (FIH Update)

✓ = Achieved



1. In order to be on key events clinical presentation, data must be presented at a major medical meeting.

*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of October 13, 2026 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.